Bioceres Crop CFO granted 375,000 stock options

Bioceres Crop Solutions Corp. reports that CFO Ezequiel Simmermacher received a grant of 375,000 Employee Stock Options (Right to Buy) covering 375,000 Ordinary Shares at an exercise price of 1.45 per share.

Rhea-AI Filing Summary

Bioceres Crop Solutions Corp. reports that CFO Ezequiel Simmermacher received a grant of 375,000 Employee Stock Options (Right to Buy) covering 375,000 Ordinary Shares at an exercise price of 1.45 per share. The options were granted on August 3, 2026 under the 2023 Omnibus Equity Incentive Plan, vest annually in three equal installments commencing June 30, 2026, and expire on June 30, 2033. Following the grant, he holds 375,000 options directly.

Insider Trade Summary

Grant/Award: 375,000 shares

Grant/Award 1 txn

Insider Simmermacher Ezequiel

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F1	375,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 375,000 contracts (Direct)

Footnotes (1)

1. F1. These options were granted on August 3, 2026, pursuant to the terms of a stock option agreement under the 2023 Omnibus Equity Incentive Plan. The options vest annually in three equal installments commencing June 30, 2026, subject to vesting conditions.

Key Figures

Options granted: 375000.0000 options Underlying Ordinary Shares: 375000.0000 shares Exercise price: 1.4500 per share +2 more

5 metrics

Options granted 375000.0000 options Employee Stock Options granted to CFO on August 3, 2026

Underlying Ordinary Shares 375000.0000 shares Ordinary Shares underlying the Employee Stock Options

Exercise price 1.4500 per share Conversion or exercise price of the options

Options after transaction 375000.0000 options Total derivative securities owned directly following the grant

Option expiration date 2033-06-30 Expiration date of the Employee Stock Options

Key Terms

Employee Stock Option (Right to Buy), 2023 Omnibus Equity Incentive Plan, vesting conditions, Ordinary Shares

4 terms

Employee Stock Option (Right to Buy) financial

"Security title listed as Employee Stock Option (Right to Buy)"

2023 Omnibus Equity Incentive Plan financial

"Granted pursuant to the 2023 Omnibus Equity Incentive Plan"

vesting conditions financial

"Options vest annually in three equal installments, subject to vesting conditions"

Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.

Ordinary Shares financial

"Underlying security title identified as Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did BIOX CFO Ezequiel Simmermacher receive?

CFO Ezequiel Simmermacher received 375,000 employee stock options in Bioceres Crop Solutions Corp. (BIOX). The options were granted on August 3, 2026, under the 2023 Omnibus Equity Incentive Plan and relate to 375,000 Ordinary Shares of the company.

What is the exercise price and expiration date of the new BIOX options?

The granted options have an exercise price of 1.45 per share and expire on June 30, 2033. These terms apply to 375,000 Employee Stock Options (Right to Buy) issued to the CFO of Bioceres Crop Solutions Corp. (BIOX).

How many BIOX ordinary shares underlie the CFO’s new option grant?

The option grant covers 375,000 Ordinary Shares of Bioceres Crop Solutions Corp. (BIOX). Each Employee Stock Option (Right to Buy) is exercisable for one Ordinary Share, subject to the vesting schedule and other terms of the 2023 Omnibus Equity Incentive Plan.

What is the vesting schedule for the new BIOX stock options?

The options vest annually in three equal installments commencing June 30, 2026. Vesting is subject to specified vesting conditions under the 2023 Omnibus Equity Incentive Plan and the related stock option agreement for Bioceres Crop Solutions Corp. (BIOX).

Under which plan were the BIOX CFO’s new options granted?

The 375,000 options were granted under Bioceres Crop Solutions Corp.’s 2023 Omnibus Equity Incentive Plan. This plan governs the terms, including vesting conditions and exercise rights, for equity awards such as the CFO’s Employee Stock Option (Right to Buy) grant in BIOX.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 02:45 PM Accepted by SEC EDGAR 08/04/2026 - 02:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simmermacher Ezequiel

(Last) (First) (Middle)

CALLE 64 S/N

(Street)

PILAR BUENOS AIRES 1629

(City) (State) (Zip)

ARGENTINA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bioceres Crop Solutions Corp. [ BIOX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$1.45	08/03/2026		A		375,000		(1)	06/30/2033	Ordinary Shares	375,000	$0.00	375,000	D

Explanation of Responses:

1. These options were granted on August 3, 2026, pursuant to the terms of a stock option agreement under the 2023 Omnibus Equity Incentive Plan. The options vest annually in three equal installments commencing June 30, 2026, subject to vesting conditions.

	/s/ Ezequiel Simmermacher	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)